Phaseline

Companies › NeuroTherapia

NeuroTherapia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTRX-07
CB2 agonist
CNR2Phase 2Alzheimer Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07058688NTRX-07Phase 2Alzheimer DiseaseNeurologyFeb 2026

Targets

CNR2 (1)

Companies with the same targets

IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed

Companies built like this

IGC Pharma Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.